+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The World Market for Molecular Diagnostics Tests, 11th Edition

  • PDF Icon

    Report

  • 296 Pages
  • November 2022
  • Region: Global
  • Kalorama Information
  • ID: 5367417

The 11th Edition report of the clinical molecular testing industry provides marketing sizing and forecasts for in vitro diagnostics (IVDs) over a five-year period. There is a market in excess of $21 billion for molecular testing technologies.  For comparison purposes, this is nearly the size of the IVD market two decades ago.  The majority of the market is COVID-19, but there remains a sizable market for other molecular IVD applications, from cancer to transplant typing to infectious diseases. This report assess the business opportunity in each of these areas.  Molecular diagnostics proved themselves during the COVID-19 pandemic, but the market in 2022 is a different place.  

Overall Market

  • Infectious Disease Molecular Diagnostics (COVID-19, Hepatitis, HIV, Respiratory, STI, HAIs, Others)
  • Cancer Molecular Diagnostic Markets (Blood-based and Tissue-based)
  • Genetic Molecular Diagnostic Markets (SNPs, Inherited, NIPT, Other)
  • Blood Banking Molecular Diagnostics Markets
  • Transplantation Molecular Diagnostic Markets
  • Regional Molecular Diagnostics Markets (North America, Europe, Asia, Global)

Molecular diagnostics proved themselves during the COVID-19 pandemic, but the market in 2022 is a different place.  

This report is published as the industry experienced accelerated installed bases and new product introductions.  Molecular diagnostics has always been a fast-evolving and dynamic field.  Taken together, it is the fastest-growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and therapy, organ matching, blood safety, and the diagnosis of latent and neonatal conditions.

Companies considered in this report include:

  • Roche
  • Abbot
  • Thermo Fisher
  • Meridian Bioscience
  • Myriad
  • Perkin Elmer
  • Cepheid
  • BioMérieux
  • Promega
  • QuantuMDX
  • QuidelOrtho
  • Hologic

Table of Contents

CHAPTER 1: EXECUTIVE SUMMARY
  • MOLECULAR DIAGNOSTICS IN THE SPOTLIGHT
  • Figure 1-1: Molecular Diagnostics Market (w COVID-19 and w/out COVID-19, 2021 ($B)
  • Hundreds of PCR Tests on the Market, U.S. Labs Settle on a Few
  • Table 1-1: Table 1-1: COVID-19 Molecular Testing Market, First Half-Year 2020, Full Year 2020, and Q 2021 ($M)
  • Figure 1-2: Estimated COVID-19 Molecular Diagnostic Revenue, Q1 2020-Q1 2021  COVID-19 Market
  • EMERGING TRENDS
  • Automation
  • Table 1-2: Market-Available Molecular POC Diagnostic Platforms Molecular Point of Care
  • Next-Generation Sequencing on the Rise
  • LDT Regulation and COVID-19
  • Reimbursement Environment
  • Thermo and Qiagen Merger
  • Table 1-3: Complementary diagnostic products offered by Thermo Fisher, Qiagen
  • CRISPR, Sequencing and COVID-19
  • THE GLOBAL MOLECULAR DIAGNOSTICS MARKET IN THE ERA OF COVID-19
  • Table 1-4: Non-COVID-19 Molecular Diagnostics Market, 2020-2026 ($M)
CHAPTER 2: COVID-19 MOLECULAR DIAGNOSTIC MARKET ANALYSIS
  • MAJOR IVD PLAYERS SEE BRISK COVID-19 TEST SALES
  • Table 2-1: COVID-19 Molecular Detection Tests from Major Suppliers
  • Figure 2-1: COVID-19 Molecular Diagnostics Monthly Volume
  • Figure 2-2: COVID-19 Molecular Diagnostics Monthly Test Volume
  • Table 2-2a: COVID-19 Molecular Diagnostics Revenues by Region Estimated: North America, Europe, APAC, ROW, LATAM, World, Q1 2020-Q1 2021 (in $)
  • Table 2-2b: COVID-19 Molecular Diagnostics Shares by Region Estimated: North America, Europe, APAC, ROW, LATAM, World, 2020-Q1 2021 (%)
  • Figure 2-3: COVID-19 Molecular Diagnostics Estimated Revenue by Region
  • Figure 2-4: COVID-19 Revenue Shares by Region
  • NORTH AMERICA
  • Table 2-3: COVID-19 Tests, North America (early June 2021)
  • Figure 2-5: USA - New Cases per Day
  • Figure 2-6: USA Daily Testing Volume
  • Figure 2-7: Canada - New Cases per Day
  • Figure 2-8: Canada Daily Testing Volume
  • EUROPE
  • Table 2-4: COVID Tests, Europe (early June 2021)
  • Figure 2-9: Italy - New Cases per Day
  • Figure 2-10: Italy Daily Testing Volume
  • Figure 2-11: Russia - New Cases per Day
  • Figure 2-12: Russia Daily Testing Volume
  • APAC
  • Table 2-5: COVID Tests APAC Region (early June 2021)
  • Figure 2-13: India - New Cases per Day
  • Figure 2-14: India Daily Testing Volume
  • Figure 2-15: Australia - New Cases per Day
  • Figure 2-16: Australia Daily Testing Volume
  • LATIN AMERICA
  • Table 2-6: Latin America COVID Testing (early June 2021)
  • Figure 2-17: Colombia - New Cases per day
  • Figure 2-18: Colombia Daily Testing Volume
  • Figure 2-19: Chile - New Cases per Day
  • Figure 2-20: Chile Daily Testing Volume
  • REST-OF-WORLD
  • Table 2-7: Rest of World Testing (early June 2021)
  • Figure 2-21: Turkey - New Cases per Day
  • Figure 2-22: Turkey Daily Testing Volume
  • Figure 2-23: South Africa - New Cases per Day
  • Figure 2-24: South Africa Daily Testing Volume
  • COVID TESTING MARKET COMPUTATION METHODOLOGY
  • TEST VENDORS
  • Table 2-8: Other PCR Tests Products on the Market
  • TESTING TRENDS, RECOMMENDATIONS, AND CONSENSUS TAKING SHAPE
  • CHAPTER 3: MARKETS FOR OTHER MOLECULAR DIAGNOSTIC TESTS
  • Table 3-1a: Molecular Diagnostic Market, 2021 and 2026 by Category ($M)
  • Table 3-1b: Molecular Diagnostic (non-COVID) Market, by Region 2021 ($M)
  • Figure 3-1: Molecular Diagnostics (non-COVID) Market by Region 2021 ($M)
  • RECENT PRODUCT INTRODUCTIONS AND REGULATORY APPROVALS
  • Table 3-2: Recent Product Introduction
  • Table 3-3: Recent Regulatory Approvals and Related Announcements
  • INFECTIOUS DISEASES
  • Respiratory Diseases: COVID-19 Impact
  • Mycobacteria/Tuberculosis: Market and COVID-19 Impact
  • Product Developments
  • Hospital-Acquired Infections (HAIs): Market and COVID-19 Impact
  • COVID as a hospital infection?
  • Vendors
  • Sexually Transmitted Infections: Market and COVID-19 Impact
  • Increased Vendor Activity in Molecular Trichomoniasis vaginalis (TV)
  • Hepatitis: COVID-19 Impact
  • New HCV Screening Guidelines
  • Table 3-4: Selected Molecular Hepatitis Tests
  • HIV Market and COVID-19 Impact
  • Table 3-5: Selected Molecular Test Products for HIV
  • NAT BLOOD SCREENING
  • COVID-19 Impact
  • Other Trends
  • Declining Blood Transfusions in Developed Markets
  • MOLECULAR HISTOLOGY AND CYTOLOGY DIAGNOSTICS
  • COVID-19 Impact
  • HPV
  • Eliminating HPV Threat? Lancet Public Health Study
  • COVID-19 Impact
  • Product Developments
  • MARKETS FOR MOLECULAR CANCER DIAGNOSTICS
  • Cancer Molecular Blood Markers - COVID-19 Impact
  • Other Trends
  • Liquid Biopsy
  • MOLECULAR TRANSPLANT DIAGNOSTICS
  • COVID-19
  • Table 3-6: Selected Innovations in the Field of Molecular Transplant Diagnostics
  • MOLECULAR INHERITED DISEASES DIAGNOSTICS
  • Inherited Diseases - COVID-19 Impact
  • Thrombophilia and Coagulation Markers
  • Non-Invasive Prenatal Testing (NIPT)
  • Promising NIPT Studies
  • Inherited Disease Tests
  • MOLECULAR DIAGNOSTICS MARKET DEALS, COLLABORATIONS, ACQUISITIONS
  • Table 3-7: Selected Deals
CHAPTER 4: TRENDS TO WATCH - SEQUENCING, CRISPR, AUTOMATION SEQUENCING
  • Avoiding New Waves of Infection
  • COVID and NGS
  • NGS and Inherited Disease
  • NGS and Companion Diagnostics
  • Table 4-1: Selected Clinical NGS Platforms in the Market
  • Outlook For NGS in Molecular Diagnostics
  • Figure 4-1: Percent of the MDX Market Revenues for Tests Using NGS 2020 and 2025
  • Evolving Informatics Solutions in Clinical Sequencing
  • Sample Preparation and Quality Control
  • LAB AUTOMATION AND MOLECULAR DIAGNOSTICS
  • Table 4-2: Selected Automated Molecular Test Instrument Platforms
  • Table 4-3: Selected FDA Declared EUA Tests
  • CRISPR AND MOLECULAR DIAGNOSTICS
  • Table 4-4: CRISPR Innovations CRISPR and COVID-19
CHAPTER 5: COMPANY PROFILES
  • ABBOTT DIAGNOSTICS
  • Company Overview
  • Table 5-1: Abbott Diagnostics' Recent Revenue History ($M), 2015-2020
  • Figure 5-1a: Abbott Diagnostics' Molecular Diagnostics Revenue History ($M), 2016- Q1 2021
  • Figure 5-1b: Abbott Diagnostics' Molecular Diagnostics Revenue History ($M), 2016- Q1 2021 Financial Review
  • COVID-19
  • FDA approval of ALK Break Apart FISH Probe Kit
  • Alinity s System
  • WHO prequalification (PQ) approval of viral load test
  • ADVANCED CELL DIAGNOSTICS (BIO-TECHNE)
  • Company Overview
  • AGENA BIOSCIENCE
  • Company Overview
  • AGENDIA BV
  • Company Overview
  • AGILENT TECHNOLOGIES (INCL. DAKO)
  • Company Overview
  • Table 5-2: Agilent Technologies' Recent Revenue History ($ millions)
  • Figure 5-2: Diagnostics and Genomics Revenue ($M), 2016- Q1 2021 Financial Review
  • AIDIAN OY
  • Company Overview
  • ALTONA DIAGNOSTICS
  • Company Overview
  • AMOY DIAGNOSTICS
  • Company Overview
  • APPLIED SPECTRAL IMAGING
  • Company Overview
  • ARUP LABORATORIES
  • Company Overview
  • Table 5-3: ARUP Labs' Recent Revenue History ($ millions)
  • ASURAGEN INC. (BIO-TECHNE)
  • Company Overview
  • BECTON, DICKINSON & CO. (BD)
  • Company Overview
  • Business Segments
  • BD Medical.
  • BD Life Sciences
  • BD Interventional
  • Recent Acquisitions
  • TVA Medical, Inc.
  • C. R. Bard, Inc.
  • CareFusion Corporation
  • Recent Divestitures
  • Advanced Bio-processing
  • Respiratory Solutions and Vyaire Medical
  • Leading Position in the Flow Cytometry Market
  • Revenue and Growth
  • Figure 5-3: BD Quarterly Revenues ($M)
  • Molecular Diagnostics Focus
  • BEIJING GENOMICS INSTITUTE (BGI)
  • Company Overview
  • Complete Genomics
  • Sanger Sequencing
  • BERRY GENOMICS
  • Company Overview
  • BINX HEALTH
  • Company Overview
  • BIO-RAD LABORATORIES, INC.
  • Company Overview
  • Recent Revenue History
  • Table 5-4: Bio-Rad Revenue History ($M)
  • BIOCARTIS
  • Company Overview
  • Financial Review
  • Table 5-5: Biocartis' Recent Revenue History ($ millions)
  • BIODESIX
  • Company Overview
  • BIOMEME, INC
  • Company Overview
  • Company Overview
  • Table 5-6: bioMérieux Revenue History
  • Figure 5-4: bioMérieux’s Molecular Biology and Microbiology Segments
  • Molecular
  • BIONEER
  • Company Overview
  • AccuPower COVID-19 Real-Time RT-PCR Kit
  • CAREDX, INC.
  • Company Overview
  • Figure 5-5: CareDx Recent Revenues
  • AlloMap Tests
  • AlloSure Tests
  • Products Offered by CareDx
  • CREDO BIOSCIENCE
  • Company Overview
  • CTK BIOTECH
  • Company Overview
  • DANAHER (CEPHEID AND LEICA BIOSYSTEMS)
  • Company Overview
  • Life Sciences Business
  • Diagnostics Business
  • Cepheid
  • Leica Biosystems
  • Danaher’s 2019 Performance and 2020 Expectations
  • Figure 5-6: Danaher Recent Revenues
  • DIASORIN
  • Company Overview
  • EIKEN CHEMICAL
  • Company Overview
  • EXACT SCIENCES CORP.
  • Company Overview
  • FLUIDIGM CORPORATION
  • Company Overview
  • GENMARK DIAGNOSTICS (ROCHE)
  • Company Overview
  • Figure 5-7: GenMark Recent Revenues
  • GENOTYPIC TECHNOLOGY PVT. LTD.
  • Company Overview
  • GREINER BIO-ONE GMBH
  • Company Overview
  • GRIFOLS, S. A
  • Company Overview
  • Molecular Immunohematology and Specialty Testing Products
  • NAT Blood Screening
  • HOLOGIC, INC.
  • Company Overview
  • Figure 5-8:  Hologic Recent Revenues
  • Table 5-7: Hologic's Recent Revenue History ($ millions)
  • ILLUMINA, INC.
  • Company Overview
  • Table 5-8: Illumina's Recent Revenue History ($ millions)
  • Figure 5-8:  Illumina Recent Revenues
  • Table 5-9: Illumina’s Technology Platforms and Targeted Applications
  • IMMUCOR, INC.
  • Company Overview
  • Transfusion Diagnostics
  • MERIDIAN BIOSCIENCE INC
  • Company Overview
  • Figure 5-8:  Meridian Recent Revenues
  • MESA BIOTECH, INC. (THERMO)
  • Company Overview
  • MOLBIO DIAGNOSTICS PVT. LTD.
  • Company Overview
  • MYRIAD GENETICS, INC.
  • Company Overview
  • Financial Review
  • Table 5-10: Myriad Genetics' Recent Revenue History ($ millions)
  • NANOSTRING TECHNOLOGIES, INC.
  • Company Overview
  • NEUROMODX
  • Company Overview
  • OXFORD NANOPORE TECHNOLOGIES LTD
  • Company Overview
  • PERKINELMER INC.
  • Company Overview
  • PRESCIENT MEDICINE HOLDINGS (AUTOGENOMICS)
  • Company Overview
  • PROMEGA CORPORATION
  • Company Overview
  • QIAGEN
  • Company Overview
  • Thermo Fisher Purchase
  • Table 5-11: Complementary diagnostic products offered by Thermo Fisher, Qiagen
  • Table 5-12: QIAGEN's Recent Revenue History ($ millions)
  • QUANTUMDX GROUP.
  • Company Overview
  • QUIDEL CORPORATION
  • Company Overview
  • RHEONIX, INC.
  • Company Overview
  • Products
  • ROCHE DIAGNOSTICS
  • Company Overview
  • COVID-19 Early Actions
  • Financial Review
  • Figure 5-8: Roche Recent Revenue
  • Table 5-13: Roche Diagnostics' Recent Revenue History ($M)
  • Recent Regulatory and Product Developments
  • Cobas Liat System - POC
  • Acquisition of GenMark Diagnostics
  • Sysmex Agreement
  • Non-Exclusive 15-Year Collaboration With Illumina
  • Approval for cobas EZH2 Mutation Test
  • June 2020 - partnership with SpeeDX
  • Stratos Genomics
  • HPV
  • PLUS Cytoogy
  • ASPiRATION study
  • Cobas Zika test for blood screening
  • FDA approval of Babesia test
  • Release of NAVIFY Guidelines app
  • EBV and BKV Tests on the cobas 6800/8800 Systems
  • Expanded use of VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC)
  • FDA 510(k) clearance for cobas TV/MG test
  • SEEGENE
  • Company Overview
  • SEKISUI DIAGNOSTICS LLC
  • Company Overview
  • SHERLOCK BIOSCIENCES
  • Company Overview
  • T2 BIOSYSTEMS
  • Company Overview
  • THERMO FISHER SCIENTIFIC INC.
  • Company Overview
  • Table 5-14: Thermo Fisher's Recent Revenue History ($ millions)
  • Transplant Diagnostics
  • qPCR
  • Sequencing
  • Qiagen Acquisition Scrapped
  • VELA DIAGNOSTICS
  • Company Overview
  • VERACYTE, INC.
  • Company Overview

Companies Mentioned

  • ARUP
  • Abbott
  • Asuragen
  • BGI
  • Becton, Dickinson &Co.
  • Bio-Rad
  • BioMérieux
  • Biocartis
  • CTK
  • CareDX
  • Cepheid
  • Credo
  • Eiken
  • Greiner Bio-One
  • Grifols
  • Hologic
  • Illumina
  • Leica Biosystems
  • Leica Biosystems   
  • Meridian Bioscience
  • Myriad
  • Perkin Elmer
  • Promega
  • Qiagen
  • QuantuMDX
  • QuidelOrtho
  • Roche
  • T2
  • Thermo Fisher
  • Vela Diagnostics